 Leigh Perreault
Concepts (335)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prediabetic State | 24 | 2024 | 251 | 6.530 |
Why?
| | Diabetes Mellitus, Type 2 | 50 | 2024 | 2529 | 4.760 |
Why?
| | Insulin Resistance | 34 | 2025 | 1221 | 4.040 |
Why?
| | Hypoglycemic Agents | 23 | 2023 | 1380 | 2.910 |
Why?
| | Obesity | 30 | 2025 | 3007 | 2.710 |
Why?
| | Blood Glucose | 31 | 2023 | 2286 | 2.410 |
Why?
| | Weight Loss | 16 | 2025 | 794 | 2.230 |
Why?
| | Muscle, Skeletal | 22 | 2025 | 1747 | 2.190 |
Why?
| | Cardiovascular Diseases | 15 | 2020 | 2091 | 1.950 |
Why?
| | Insulin | 20 | 2024 | 2472 | 1.710 |
Why?
| | Sphingolipids | 7 | 2024 | 80 | 1.610 |
Why?
| | Diabetes Mellitus | 11 | 2023 | 1078 | 1.530 |
Why?
| | Triglycerides | 11 | 2024 | 510 | 1.510 |
Why?
| | Benzhydryl Compounds | 3 | 2017 | 76 | 1.390 |
Why?
| | Glucose Intolerance | 8 | 2020 | 146 | 1.390 |
Why?
| | Diabetic Angiopathies | 3 | 2017 | 250 | 1.380 |
Why?
| | Diglycerides | 6 | 2024 | 60 | 1.250 |
Why?
| | Diabetes Complications | 2 | 2019 | 222 | 1.070 |
Why?
| | Overweight | 7 | 2022 | 589 | 1.050 |
Why?
| | Glucosides | 2 | 2017 | 50 | 1.030 |
Why?
| | Glucagon-Like Peptide 1 | 3 | 2023 | 133 | 0.960 |
Why?
| | Life Style | 12 | 2020 | 479 | 0.950 |
Why?
| | Exercise | 12 | 2025 | 2113 | 0.920 |
Why?
| | Metformin | 13 | 2023 | 330 | 0.870 |
Why?
| | Primary Health Care | 6 | 2023 | 1757 | 0.850 |
Why?
| | Receptors, Gastrointestinal Hormone | 1 | 2023 | 7 | 0.830 |
Why?
| | Anti-Obesity Agents | 2 | 2024 | 59 | 0.810 |
Why?
| | Adipose Tissue | 5 | 2025 | 645 | 0.810 |
Why?
| | Glucose Tolerance Test | 15 | 2021 | 367 | 0.810 |
Why?
| | Cannabidiol | 1 | 2025 | 126 | 0.780 |
Why?
| | Glucose Clamp Technique | 11 | 2024 | 197 | 0.780 |
Why?
| | Adult | 56 | 2025 | 39319 | 0.760 |
Why?
| | Goals | 2 | 2021 | 177 | 0.750 |
Why?
| | Humans | 97 | 2025 | 141284 | 0.740 |
Why?
| | Dronabinol | 1 | 2025 | 240 | 0.740 |
Why?
| | Nutrition Therapy | 1 | 2022 | 36 | 0.710 |
Why?
| | Marijuana Use | 1 | 2025 | 221 | 0.690 |
Why?
| | Liver | 4 | 2014 | 1821 | 0.690 |
Why?
| | Middle Aged | 46 | 2025 | 34658 | 0.680 |
Why?
| | Health Equity | 1 | 2023 | 107 | 0.680 |
Why?
| | Primary Care Nursing | 1 | 2019 | 4 | 0.630 |
Why?
| | Hyperglycemia | 4 | 2014 | 365 | 0.620 |
Why?
| | Male | 61 | 2025 | 70140 | 0.620 |
Why?
| | Female | 66 | 2025 | 75814 | 0.610 |
Why?
| | Lipid Metabolism | 5 | 2025 | 522 | 0.580 |
Why?
| | Peripheral Vascular Diseases | 1 | 2019 | 104 | 0.570 |
Why?
| | Obesity Management | 1 | 2018 | 8 | 0.570 |
Why?
| | Insulin, Long-Acting | 1 | 2019 | 64 | 0.570 |
Why?
| | Microvessels | 1 | 2019 | 86 | 0.570 |
Why?
| | Infant, Newborn, Diseases | 1 | 2019 | 113 | 0.560 |
Why?
| | Awareness | 1 | 2019 | 102 | 0.550 |
Why?
| | Body Mass Index | 12 | 2024 | 2390 | 0.550 |
Why?
| | Cannabis | 1 | 2025 | 510 | 0.550 |
Why?
| | Fasting | 4 | 2020 | 283 | 0.530 |
Why?
| | Ceramides | 5 | 2024 | 117 | 0.520 |
Why?
| | Policy | 1 | 2018 | 146 | 0.520 |
Why?
| | Weight Reduction Programs | 2 | 2017 | 117 | 0.510 |
Why?
| | Precision Medicine | 1 | 2021 | 435 | 0.510 |
Why?
| | Risk Management | 1 | 2017 | 91 | 0.510 |
Why?
| | Risk Factors | 19 | 2023 | 10490 | 0.500 |
Why?
| | Incretins | 2 | 2021 | 21 | 0.500 |
Why?
| | Rest | 2 | 2017 | 128 | 0.490 |
Why?
| | Choristoma | 1 | 2015 | 21 | 0.470 |
Why?
| | Sleep Deprivation | 5 | 2021 | 204 | 0.450 |
Why?
| | Insulin-Secreting Cells | 2 | 2010 | 382 | 0.440 |
Why?
| | Weight Gain | 4 | 2019 | 536 | 0.410 |
Why?
| | Inflammation | 1 | 2025 | 2840 | 0.410 |
Why?
| | Sarcolemma | 3 | 2024 | 38 | 0.400 |
Why?
| | Glucose | 4 | 2023 | 1027 | 0.390 |
Why?
| | Phenols | 1 | 2013 | 111 | 0.380 |
Why?
| | Randomized Controlled Trials as Topic | 4 | 2022 | 1610 | 0.380 |
Why?
| | Clinical Trials as Topic | 1 | 2017 | 1035 | 0.380 |
Why?
| | Lipids | 4 | 2024 | 686 | 0.370 |
Why?
| | Physical Endurance | 5 | 2020 | 276 | 0.350 |
Why?
| | Fenofibrate | 1 | 2011 | 27 | 0.340 |
Why?
| | Glucagon-Like Peptides | 2 | 2022 | 65 | 0.330 |
Why?
| | Athletes | 7 | 2024 | 413 | 0.330 |
Why?
| | Hypolipidemic Agents | 1 | 2011 | 93 | 0.320 |
Why?
| | Phosphatidylcholines | 2 | 2024 | 131 | 0.320 |
Why?
| | Dipeptidyl-Peptidase IV Inhibitors | 1 | 2010 | 48 | 0.320 |
Why?
| | Palmitates | 1 | 2009 | 21 | 0.320 |
Why?
| | Cross-Sectional Studies | 9 | 2024 | 5653 | 0.310 |
Why?
| | Pyrazines | 1 | 2010 | 88 | 0.310 |
Why?
| | Hospitalization | 1 | 2019 | 2264 | 0.310 |
Why?
| | Triazoles | 1 | 2010 | 163 | 0.300 |
Why?
| | Aged | 17 | 2023 | 24836 | 0.300 |
Why?
| | Energy Metabolism | 4 | 2021 | 926 | 0.290 |
Why?
| | Young Adult | 13 | 2025 | 13727 | 0.280 |
Why?
| | Biomarkers | 8 | 2023 | 4180 | 0.280 |
Why?
| | Sleep | 4 | 2021 | 882 | 0.270 |
Why?
| | Sodium-Glucose Transporter 2 | 2 | 2017 | 25 | 0.260 |
Why?
| | Risk Reduction Behavior | 3 | 2023 | 227 | 0.260 |
Why?
| | Diabetic Nephropathies | 2 | 2020 | 293 | 0.260 |
Why?
| | Sex Characteristics | 3 | 2021 | 783 | 0.250 |
Why?
| | Markov Chains | 2 | 2018 | 123 | 0.250 |
Why?
| | Absenteeism | 2 | 2018 | 52 | 0.250 |
Why?
| | Double-Blind Method | 5 | 2024 | 1992 | 0.250 |
Why?
| | Sex Factors | 5 | 2018 | 2055 | 0.240 |
Why?
| | Health Services | 2 | 2018 | 116 | 0.240 |
Why?
| | Adiponectin | 3 | 2018 | 243 | 0.230 |
Why?
| | Muscle Fibers, Skeletal | 3 | 2024 | 213 | 0.220 |
Why?
| | Remission Induction | 3 | 2019 | 306 | 0.220 |
Why?
| | Follow-Up Studies | 6 | 2021 | 5222 | 0.220 |
Why?
| | Pilot Projects | 2 | 2021 | 1820 | 0.220 |
Why?
| | Renal Insufficiency, Chronic | 2 | 2022 | 626 | 0.220 |
Why?
| | Carnitine | 2 | 2024 | 83 | 0.220 |
Why?
| | Circadian Rhythm | 3 | 2019 | 509 | 0.210 |
Why?
| | Dietary Fats | 3 | 2020 | 303 | 0.210 |
Why?
| | Lipogenesis | 2 | 2017 | 64 | 0.210 |
Why?
| | Lipoprotein Lipase | 1 | 2004 | 56 | 0.200 |
Why?
| | Hyperinsulinism | 1 | 2024 | 113 | 0.200 |
Why?
| | Physical Exertion | 1 | 2004 | 208 | 0.200 |
Why?
| | Oxidation-Reduction | 4 | 2024 | 1080 | 0.190 |
Why?
| | Healthy Lifestyle | 1 | 2023 | 35 | 0.190 |
Why?
| | Computer Simulation | 2 | 2018 | 1009 | 0.190 |
Why?
| | Diet, Reducing | 3 | 2017 | 90 | 0.190 |
Why?
| | Energy Intake | 4 | 2021 | 510 | 0.190 |
Why?
| | Socioeconomic Factors | 2 | 2018 | 1311 | 0.190 |
Why?
| | Biopsy | 3 | 2018 | 1073 | 0.180 |
Why?
| | Combined Modality Therapy | 4 | 2019 | 1243 | 0.180 |
Why?
| | Cluster Analysis | 1 | 2023 | 518 | 0.180 |
Why?
| | Endpoint Determination | 2 | 2019 | 77 | 0.180 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2024 | 2047 | 0.170 |
Why?
| | Prevalence | 2 | 2019 | 2795 | 0.170 |
Why?
| | Nephrology | 1 | 2022 | 61 | 0.170 |
Why?
| | Glucose Transporter Type 4 | 1 | 2021 | 38 | 0.170 |
Why?
| | Cytosol | 2 | 2020 | 225 | 0.170 |
Why?
| | Ambulatory Care Facilities | 1 | 2023 | 245 | 0.170 |
Why?
| | Body Weight | 4 | 2024 | 992 | 0.160 |
Why?
| | Risk Adjustment | 1 | 2020 | 81 | 0.160 |
Why?
| | Endocrinologists | 1 | 2020 | 13 | 0.160 |
Why?
| | New Zealand | 1 | 2019 | 55 | 0.160 |
Why?
| | Cytosine | 1 | 2019 | 48 | 0.150 |
Why?
| | Endoplasmic Reticulum | 2 | 2020 | 262 | 0.150 |
Why?
| | Pragmatic Clinical Trials as Topic | 1 | 2019 | 126 | 0.150 |
Why?
| | Fatty Liver | 1 | 2021 | 237 | 0.150 |
Why?
| | Fatty Acids, Nonesterified | 2 | 2019 | 158 | 0.150 |
Why?
| | Liraglutide | 1 | 2019 | 31 | 0.150 |
Why?
| | Exercise Test | 3 | 2015 | 620 | 0.140 |
Why?
| | Models, Econometric | 1 | 2018 | 36 | 0.140 |
Why?
| | Retinal Diseases | 1 | 2019 | 96 | 0.140 |
Why?
| | Postprandial Period | 1 | 2019 | 111 | 0.140 |
Why?
| | Quinolizines | 1 | 1997 | 9 | 0.140 |
Why?
| | Adolescent | 8 | 2023 | 22116 | 0.140 |
Why?
| | Colorado | 3 | 2023 | 4599 | 0.130 |
Why?
| | United States | 9 | 2023 | 15298 | 0.130 |
Why?
| | Drug Combinations | 1 | 2019 | 365 | 0.130 |
Why?
| | Antiemetics | 1 | 1997 | 48 | 0.130 |
Why?
| | Nausea | 1 | 1997 | 111 | 0.130 |
Why?
| | Referral and Consultation | 1 | 2023 | 802 | 0.130 |
Why?
| | Cholesterol, HDL | 2 | 2015 | 196 | 0.130 |
Why?
| | Tissue Plasminogen Activator | 2 | 2018 | 239 | 0.130 |
Why?
| | Health Resources | 1 | 2018 | 126 | 0.130 |
Why?
| | Cytokines | 1 | 2025 | 2079 | 0.130 |
Why?
| | Vomiting | 1 | 1997 | 128 | 0.130 |
Why?
| | Hysterectomy | 1 | 1997 | 137 | 0.130 |
Why?
| | Severity of Illness Index | 2 | 2018 | 2904 | 0.130 |
Why?
| | Odds Ratio | 1 | 2019 | 1057 | 0.120 |
Why?
| | Surgical Wound Infection | 1 | 2019 | 321 | 0.120 |
Why?
| | Patient-Centered Care | 1 | 2021 | 539 | 0.120 |
Why?
| | Patient Participation | 1 | 2019 | 427 | 0.120 |
Why?
| | Phosphatidylethanolamines | 1 | 2016 | 75 | 0.120 |
Why?
| | Delivery of Health Care | 1 | 2023 | 948 | 0.120 |
Why?
| | Blotting, Western | 2 | 2016 | 1220 | 0.120 |
Why?
| | Phenotype | 1 | 2024 | 3172 | 0.120 |
Why?
| | Eating | 2 | 2021 | 393 | 0.120 |
Why?
| | Research Design | 2 | 2019 | 1105 | 0.120 |
Why?
| | Tandem Mass Spectrometry | 2 | 2024 | 565 | 0.110 |
Why?
| | Cost-Benefit Analysis | 1 | 2018 | 612 | 0.110 |
Why?
| | Kidney Diseases | 1 | 2019 | 409 | 0.110 |
Why?
| | Treatment Outcome | 6 | 2021 | 11216 | 0.110 |
Why?
| | Exercise Therapy | 2 | 2017 | 453 | 0.110 |
Why?
| | Costs and Cost Analysis | 1 | 2015 | 219 | 0.110 |
Why?
| | Sleep Apnea Syndromes | 1 | 2015 | 90 | 0.110 |
Why?
| | Patient Compliance | 1 | 2019 | 607 | 0.110 |
Why?
| | Income | 1 | 2015 | 198 | 0.110 |
Why?
| | Somatostatin | 1 | 2014 | 57 | 0.110 |
Why?
| | Hypoglycemia | 1 | 2019 | 470 | 0.110 |
Why?
| | Logistic Models | 1 | 2019 | 2098 | 0.100 |
Why?
| | Indoles | 1 | 1997 | 472 | 0.100 |
Why?
| | Employment | 1 | 2015 | 180 | 0.100 |
Why?
| | Recovery of Function | 2 | 2015 | 684 | 0.100 |
Why?
| | Pneumonia | 1 | 2019 | 634 | 0.100 |
Why?
| | Fructose | 1 | 2014 | 117 | 0.100 |
Why?
| | Smoking | 2 | 2012 | 1576 | 0.100 |
Why?
| | Health Personnel | 1 | 2019 | 727 | 0.100 |
Why?
| | Metabolic Diseases | 1 | 2014 | 114 | 0.100 |
Why?
| | Cost of Illness | 1 | 2015 | 311 | 0.100 |
Why?
| | C-Reactive Protein | 1 | 2015 | 416 | 0.100 |
Why?
| | Multicenter Studies as Topic | 1 | 2014 | 367 | 0.100 |
Why?
| | Oxygen Consumption | 4 | 2016 | 712 | 0.100 |
Why?
| | Consensus | 3 | 2020 | 538 | 0.100 |
Why?
| | Fatty Acids, Monounsaturated | 1 | 2012 | 54 | 0.100 |
Why?
| | Qualitative Research | 1 | 2019 | 1519 | 0.090 |
Why?
| | Models, Theoretical | 1 | 2016 | 582 | 0.090 |
Why?
| | Homeostasis | 1 | 2016 | 632 | 0.090 |
Why?
| | Aged, 80 and over | 3 | 2019 | 7948 | 0.090 |
Why?
| | Adult Children | 1 | 2011 | 26 | 0.090 |
Why?
| | Mitochondria | 1 | 2018 | 962 | 0.090 |
Why?
| | Prospective Studies | 3 | 2019 | 7805 | 0.090 |
Why?
| | Placebos | 2 | 2009 | 195 | 0.090 |
Why?
| | Practice Guidelines as Topic | 1 | 2019 | 1546 | 0.090 |
Why?
| | Adipocytes | 1 | 2012 | 220 | 0.080 |
Why?
| | Diabetes, Gestational | 1 | 2015 | 318 | 0.080 |
Why?
| | Age Factors | 1 | 2018 | 3295 | 0.080 |
Why?
| | Health Behavior | 2 | 2023 | 784 | 0.080 |
Why?
| | Sitagliptin Phosphate | 1 | 2010 | 33 | 0.080 |
Why?
| | Family Health | 1 | 2011 | 194 | 0.080 |
Why?
| | Comorbidity | 1 | 2015 | 1671 | 0.080 |
Why?
| | Metabolomics | 1 | 2015 | 702 | 0.080 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2019 | 1395 | 0.080 |
Why?
| | Longevity | 1 | 2011 | 174 | 0.080 |
Why?
| | C-Peptide | 1 | 2010 | 168 | 0.080 |
Why?
| | Mitochondria, Muscle | 2 | 2021 | 120 | 0.080 |
Why?
| | Quality of Life | 3 | 2019 | 3024 | 0.080 |
Why?
| | Disease Progression | 3 | 2024 | 2808 | 0.070 |
Why?
| | Menopause | 1 | 2011 | 317 | 0.070 |
Why?
| | Leisure Activities | 1 | 2008 | 30 | 0.070 |
Why?
| | Blood Pressure | 1 | 2014 | 1740 | 0.070 |
Why?
| | Delphi Technique | 2 | 2019 | 314 | 0.070 |
Why?
| | Body Composition | 1 | 2011 | 704 | 0.060 |
Why?
| | Risk Assessment | 3 | 2015 | 3522 | 0.060 |
Why?
| | Predictive Value of Tests | 1 | 2012 | 2069 | 0.060 |
Why?
| | Fibrinogen | 2 | 2018 | 179 | 0.060 |
Why?
| | Cohort Studies | 4 | 2021 | 5809 | 0.060 |
Why?
| | Multivariate Analysis | 1 | 2009 | 1505 | 0.060 |
Why?
| | Diabetes Mellitus, Type 1 | 2 | 2012 | 3793 | 0.060 |
Why?
| | Regression Analysis | 2 | 2019 | 1013 | 0.060 |
Why?
| | Postoperative Complications | 1 | 1997 | 2831 | 0.060 |
Why?
| | Mass Screening | 1 | 2013 | 1309 | 0.060 |
Why?
| | Aging | 1 | 2015 | 1919 | 0.050 |
Why?
| | Metabolic Clearance Rate | 1 | 2004 | 115 | 0.050 |
Why?
| | Health Expenditures | 1 | 1986 | 193 | 0.050 |
Why?
| | Incidence | 3 | 2019 | 2809 | 0.050 |
Why?
| | Gene Expression Profiling | 2 | 2023 | 1761 | 0.050 |
Why?
| | Prognosis | 2 | 2023 | 4080 | 0.050 |
Why?
| | Hormones | 1 | 2004 | 138 | 0.050 |
Why?
| | Retrospective Studies | 2 | 2019 | 16447 | 0.050 |
Why?
| | Depression | 1 | 2012 | 1490 | 0.050 |
Why?
| | Menstrual Cycle | 1 | 2003 | 138 | 0.050 |
Why?
| | Gastrointestinal Diseases | 1 | 2024 | 207 | 0.050 |
Why?
| | Eligibility Determination | 1 | 2023 | 69 | 0.050 |
Why?
| | Mice, Inbred C57BL | 1 | 2013 | 5866 | 0.050 |
Why?
| | Alcohol Drinking | 1 | 2009 | 834 | 0.050 |
Why?
| | Parents | 1 | 2011 | 1439 | 0.050 |
Why?
| | Lactic Acid | 1 | 2003 | 303 | 0.050 |
Why?
| | Wakefulness | 2 | 2015 | 170 | 0.040 |
Why?
| | Animals | 3 | 2024 | 37328 | 0.040 |
Why?
| | Proportional Hazards Models | 2 | 2017 | 1268 | 0.040 |
Why?
| | Acute Disease | 1 | 2024 | 1005 | 0.040 |
Why?
| | Subcellular Fractions | 1 | 2021 | 76 | 0.040 |
Why?
| | Citric Acid Cycle | 1 | 2021 | 58 | 0.040 |
Why?
| | Sex Hormone-Binding Globulin | 1 | 2020 | 53 | 0.040 |
Why?
| | Injections, Subcutaneous | 1 | 2021 | 164 | 0.040 |
Why?
| | Motor Activity | 2 | 2015 | 717 | 0.040 |
Why?
| | Kinetics | 1 | 2004 | 1620 | 0.040 |
Why?
| | Protective Agents | 1 | 2020 | 41 | 0.040 |
Why?
| | Education | 1 | 2020 | 107 | 0.040 |
Why?
| | Stearoyl-CoA Desaturase | 2 | 2010 | 65 | 0.040 |
Why?
| | Proprotein Convertase 9 | 1 | 2020 | 87 | 0.040 |
Why?
| | Analysis of Variance | 2 | 2013 | 1312 | 0.040 |
Why?
| | Poisson Distribution | 1 | 2019 | 76 | 0.040 |
Why?
| | Stakeholder Participation | 1 | 2019 | 80 | 0.040 |
Why?
| | Time Factors | 3 | 2019 | 6951 | 0.040 |
Why?
| | E-Selectin | 1 | 2018 | 57 | 0.040 |
Why?
| | Pregnancy | 2 | 2015 | 7035 | 0.040 |
Why?
| | Subcutaneous Fat | 1 | 2019 | 81 | 0.040 |
Why?
| | Probability | 1 | 2019 | 307 | 0.040 |
Why?
| | Chemokine CCL2 | 1 | 2018 | 115 | 0.040 |
Why?
| | Primary Cell Culture | 1 | 2019 | 171 | 0.040 |
Why?
| | Intra-Abdominal Fat | 1 | 2019 | 89 | 0.030 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 2018 | 142 | 0.030 |
Why?
| | Cell Nucleus | 1 | 2020 | 607 | 0.030 |
Why?
| | Research | 1 | 2020 | 434 | 0.030 |
Why?
| | Leptin | 1 | 2018 | 238 | 0.030 |
Why?
| | Diet | 3 | 2012 | 1277 | 0.030 |
Why?
| | Case-Control Studies | 2 | 2017 | 3577 | 0.030 |
Why?
| | Biological Transport | 1 | 2017 | 409 | 0.030 |
Why?
| | Sequence Analysis, RNA | 1 | 2019 | 444 | 0.030 |
Why?
| | Adaptation, Physiological | 2 | 2010 | 561 | 0.030 |
Why?
| | Metabolome | 1 | 2019 | 366 | 0.030 |
Why?
| | Rats | 1 | 2024 | 5556 | 0.030 |
Why?
| | Fatty Acids, Unsaturated | 1 | 2016 | 97 | 0.030 |
Why?
| | Diet, Fat-Restricted | 1 | 2015 | 77 | 0.030 |
Why?
| | Longitudinal Studies | 2 | 2013 | 2929 | 0.030 |
Why?
| | Melatonin | 1 | 2015 | 163 | 0.030 |
Why?
| | Interleukin-6 | 1 | 2018 | 775 | 0.030 |
Why?
| | Kidney | 1 | 2022 | 1482 | 0.030 |
Why?
| | Blood Glucose Self-Monitoring | 1 | 2020 | 713 | 0.030 |
Why?
| | Calorimetry | 1 | 2013 | 71 | 0.020 |
Why?
| | Fatty Acids | 1 | 2016 | 446 | 0.020 |
Why?
| | Insulin Receptor Substrate Proteins | 1 | 2012 | 57 | 0.020 |
Why?
| | Risk | 1 | 2015 | 903 | 0.020 |
Why?
| | Glycerol | 1 | 2012 | 90 | 0.020 |
Why?
| | Algorithms | 1 | 2020 | 1764 | 0.020 |
Why?
| | Sleep Wake Disorders | 1 | 2015 | 305 | 0.020 |
Why?
| | RNA, Messenger | 2 | 2010 | 2815 | 0.020 |
Why?
| | Calorimetry, Indirect | 1 | 2010 | 85 | 0.020 |
Why?
| | Genetic Variation | 1 | 2015 | 993 | 0.020 |
Why?
| | Antidepressive Agents | 1 | 2012 | 243 | 0.020 |
Why?
| | Palmitic Acid | 1 | 2010 | 42 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2022 | 5948 | 0.020 |
Why?
| | Retinoid X Receptor gamma | 1 | 2009 | 4 | 0.020 |
Why?
| | Nicotine | 1 | 2012 | 339 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2019 | 2600 | 0.020 |
Why?
| | PPAR alpha | 1 | 2009 | 57 | 0.020 |
Why?
| | Polysomnography | 1 | 2010 | 240 | 0.020 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2012 | 428 | 0.020 |
Why?
| | Women's Health | 1 | 2011 | 308 | 0.020 |
Why?
| | Bicycling | 1 | 2010 | 118 | 0.020 |
Why?
| | Coronary Disease | 1 | 2011 | 373 | 0.020 |
Why?
| | Phospholipids | 1 | 2010 | 211 | 0.020 |
Why?
| | Phosphorylation | 1 | 2012 | 1753 | 0.020 |
Why?
| | Reference Values | 1 | 2009 | 803 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 983 | 0.020 |
Why?
| | Adiposity | 1 | 2012 | 520 | 0.020 |
Why?
| | Genetic Predisposition to Disease | 1 | 2015 | 2366 | 0.020 |
Why?
| | Mice | 1 | 2024 | 17969 | 0.020 |
Why?
| | Patient Education as Topic | 1 | 2011 | 771 | 0.020 |
Why?
| | Genotype | 1 | 2011 | 1854 | 0.010 |
Why?
| | Infant Care | 1 | 1986 | 44 | 0.010 |
Why?
| | Infertility | 1 | 1986 | 55 | 0.010 |
Why?
| | Health Promotion | 1 | 2011 | 749 | 0.010 |
Why?
| | Delivery, Obstetric | 1 | 1986 | 162 | 0.010 |
Why?
| | Maternal Health Services | 1 | 1986 | 103 | 0.010 |
Why?
| | Follicular Phase | 1 | 2003 | 39 | 0.010 |
Why?
| | Anaerobic Threshold | 1 | 2003 | 28 | 0.010 |
Why?
| | Spectrophotometry, Ultraviolet | 1 | 2003 | 85 | 0.010 |
Why?
| | Contraception | 1 | 1986 | 165 | 0.010 |
Why?
| | Luteal Phase | 1 | 2003 | 46 | 0.010 |
Why?
| | Abortion, Induced | 1 | 1986 | 106 | 0.010 |
Why?
| | Catecholamines | 1 | 2003 | 89 | 0.010 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2011 | 2122 | 0.010 |
Why?
| | Heart Rate | 1 | 2003 | 835 | 0.010 |
Why?
| | Infant, Newborn | 1 | 1986 | 6270 | 0.010 |
Why?
|
|
Perreault's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|